A new study reveals a shocking jump in "biological age" among Gen-X, Millennials, and Gen-Z—and it might explain the rise in early-onset cancers.
Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable. Read more on NTRA stock here.
I'm Larry Biegelsen, the Medical Device Analyst at Wells Fargo. Welcome to the final call in our 2026 MedTech Innovation Spotlight Series. I'm pleased to be joined by Inspire Medical's management team ...
China's office workers are worrying whether their jobs can be done by artificial intelligence - and whether their companies will make the switch When a friend checked in on a Meituan employee late ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results